scispace - formally typeset
W

William J. Tremaine

Researcher at Mayo Clinic

Publications -  290
Citations -  26053

William J. Tremaine is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Ulcerative colitis & Inflammatory bowel disease. The author has an hindex of 80, co-authored 282 publications receiving 24233 citations. Previous affiliations of William J. Tremaine include University of Paris & Cedars-Sinai Medical Center.

Papers
More filters
Journal ArticleDOI

An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease☆☆☆

TL;DR: An 1800-mg intravenous loading dose of azathioprine is safe and may decrease the time to response to < or = 4 weeks in patients with Crohn's disease.
Journal ArticleDOI

Symptomatic overlap between irritable bowel syndrome and microscopic colitis.

TL;DR: The clinical symptom‐based criteria for irritable bowel syndrome are not specific enough to rule out the diagnosis of microscopic colitis, so patients with suspected diarrhea‐predominant irritable Bowel Dis 2006 should undergo biopsies of the colon to investigate for possible microscopiccolitis.
Journal ArticleDOI

Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study.

TL;DR: There was a positive association between IBD status (patient vs control) versus EIM, but not AD, and a significant positive link between disease type (familial or sporadic) versus either EIM or AD was not detected.
Journal ArticleDOI

Sequential histologic evaluations in collagenous colitis. Correlations with disease behavior and sampling strategy.

TL;DR: It is concluded that histologic resolution of collagenous colitis can occur and it is associated with loss of symptoms, and rectosigmoid biopsies underestimate the diagnosis.
Journal ArticleDOI

Lymphocytic colitis: clinical features, treatment, and outcomes.

TL;DR: Lymphocytic colitis typically presents in elderly patients as chronic diarrhea, as do weight loss, fecal incontinence, and concomitant autoimmune disorders, and many empiric treatment options are used, but overall response rates are disappointing.